AZN250103C53000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
AstraZeneca (AZN) Gets a Buy From J.P. Morgan
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6
EST Jan 2nd Afternoon Delivery - In the last two hours of trading, 4 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
AstraZeneca Announces Share Capital and Voting Rights Update
AstraZeneca (AZN.US) "Osimertinib" has been approved for a new indication in China.
On January 2nd, the National Medical Products Administration website showed that AstraZeneca (AZN.US)'s application for the new indication of Osimertinib has officially been approved.
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Express News | AstraZeneca: Tarisudil has been approved in China for the treatment of EGFR mutation stage III unresectable non-small cell lung cancer.
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer
Express News | Organoid technology product and solution provider, Berthe Biology, has completed Series A+ financing.
Takeda-backed Ascentage Pharma Files for $100M IPO
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Express News | Daiichi Sankyo's datopotamab deruxtecan has been approved in Japan for the treatment of breast cancer.